Targeting a protein to reduce SARS-CoV-2 entry in oral cells.
Targeting Grainyhead-Like 2 Suppresses Entry Factors of SARS-CoV-2 in Epithelial Cells of Oral Mucosa.
This study is looking at how a protein called GRHL2 helps the SARS-CoV-2 virus enter cells in the mouth, with the goal of finding new treatments that could lower the chances of getting COVID-19 through oral exposure.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10598134 on NIH RePORTER |
What this research studies
This research investigates how a specific protein, Grainyhead-Like 2 (GRHL2), influences the entry of the SARS-CoV-2 virus into epithelial cells found in the oral mucosa. By understanding the role of GRHL2 in regulating the expression of viral entry factors like ACE2 and TMPRSS2, the researchers aim to develop therapies that could inhibit the virus's ability to infect these cells. The study involves both in vitro experiments with human oral keratinocytes and in vivo models to assess the effectiveness of small-molecule inhibitors targeting GRHL2. Patients may benefit from new treatment strategies that could reduce the risk of COVID-19 infection through the oral route.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for COVID-19, particularly those with conditions that may affect oral mucosal health.
Not a fit: Patients who are not at risk for COVID-19 or do not have significant oral mucosal involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the risk of SARS-CoV-2 infection in patients.
How similar studies have performed: Other research has shown promise in targeting viral entry factors, suggesting that this approach could be effective.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Chen, Wei — University of California Los Angeles
- Study coordinator: Chen, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.